A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Study of SHR-1701 or Placebo in Combination With BP102 (Biosimilar to Bevacizumab) and XELOX in First-line Treatment of mCRC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 site in 1 country62 target enrollmentJune 22, 2021

ConditionsMetastatic Colorectal Cancer (mCRC)

InterventionsSHR-1701、 BP102 、XELOX placebo、 BP102、 XELOX

DrugsSHR-1701、 BP102 、XELOX placebo、 BP102、 XELOX

Overview

Phase: Phase 2
Intervention: SHR-1701、 BP102 、XELOX
Conditions: Metastatic Colorectal Cancer (mCRC)
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment: 62
Locations: 1
Primary Endpoint: Phase 2:ORR
Status: Terminated
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials Related News

Overview

Brief Summary

This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in first-line treatment of patients with mCRC.

Registry

clinicaltrials.gov

Start Date

June 22, 2021

End Date

April 17, 2024

Last Updated

11 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with unresectable recurrent or metastatic adenocarcinoma of the colon or rectum confirmed histologically
•For subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be ≥12 months after the last administration of neoadjuvant or adjuvant therapy
•At least 1 measurable lesion according to RECIST V1.1
•The vital organs are functioning well
•ECOG score is 0 \~ 1
•Contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug

Exclusion Criteria

•Recurrent or metastatic lesions can be treated with radical surgery
•Presence of central nervous system or meningeal metastases;
•Moderate and severe ascites of clinical symptoms;Uncontrolled or moderate or greater pleural effusion or pericardial effusion
•Poorly controlled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the case of regular antihypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy
•Severe cardiovascular and cerebrovascular diseases;Have clinical heart symptoms or diseases that are not well controlledSubjects with a history of myocardial infarction or unstable angina pectoris
•Subject with current interstitial pneumonia or interstitial lung disease, or with a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy
•Previous treatment with targeted T cell costimulatory molecules and immune checkpoint inhibitors;Previous treatment with antiepidermal growth factor receptor or any antiangiogenic drug